Daiichi Slams Seagen's Bid To Nix Cancer Drug Patent Award
Japanese drugmaker Daiichi Sankyo urged a federal court to uphold an arbitral award nixing U.S. biotechnology company Seagen's claims seeking tens of billions of dollars in a dispute over cancer drug...To view the full article, register now.
Already a subscriber? Click here to view full article